GMP Violations Won’t Trigger Breach Of DOJ Compliance Agreement, Government Attorneys Say
Executive Summary
Responding to concerns about ‘over criminalization’ of companies subject to deferred prosecution agreements, FDA and DOJ attorneys note that getting a form 483 won’t breach compliance provisions. Avanos Medical’s 2021 agreement is to be model going forward.
You may also be interested in...
US DOJ Settles With St. Jude, Alere, Avanos For Total Of $88M
The settlements resolve False Claims Act allegations against St. Jude and Alere, as well as misbranding allegations against Avanos Medical.
US Enforcement 2019: Compounding, Opioids Top Priorities But Beware Of REMS Violations, Too
Drug manufacturer reimbursement support services also are garnering a growing amount of enforcement attention, and misleading promotion - whether on- or off-label - remains on the radar of government investigators.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.